Eventide Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Eventide Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$400K	Buy	3,287 +492	+18%	+$51.4K	0.01%	250
2026 Q1	$279K	Buy	+2,795	New	+$247K	﹤0.01%	253
2023 Q4	–	Sell	-320,000	Closed	-$5.34M	–	165
2023 Q3	$5.34M	Hold	320,000	–	–	0.1%	134
2023 Q2	$8.84M	Buy	+320,000	New	+$8.01M	0.15%	123
2018 Q1	–	Sell	-275,000	Closed	-$5.72M	–	148
2017 Q4	$5.72M	Buy	275,000 +150,000	+120%	+$2.66M	0.3%	81
2017 Q3	$2.21M	Hold	125,000	–	–	0.13%	100
2017 Q2	$1.41M	Buy	+125,000	New	+$1.34M	0.09%	103

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Eventide Asset Management's PTGX Position: Q2 2026 in Review

Eventide Asset Management increased its Protagonist Therapeutics (PTGX) stake by 18% in Q2 2026, buying an estimated $51.4K and bringing the position to 3,287 shares worth $400K. The position accounts for 0.01% of the portfolio, ranked #250.

Eventide Asset Management first reported a position in PTGX in Q2 2017 and has held it in 7 quarters since. The position peaked at $8.84M in Q2 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Eventide Asset Management held 3,287 shares of Protagonist Therapeutics worth $400K as of Q2 2026.
Eventide Asset Management bought 492 Protagonist Therapeutics shares in Q2 2026, an estimated $51.4K.
Protagonist Therapeutics made up 0.01% of Eventide Asset Management's portfolio in Q2 2026, its #250 holding.
Eventide Asset Management first reported a position in Protagonist Therapeutics in Q2 2017 and has held it in 7 quarters since.
Eventide Asset Management's Protagonist Therapeutics position peaked at $8.84M in Q2 2023.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.